Anti-CD40 Antibodies and Methods of Use (Apexigen Patent Grant)
Summary
USPTO granted US Patent 12,606,632 B2 to Apexigen, Inc. on April 21, 2026. The patent covers high affinity anti-CD40 monoclonal antibodies and related compositions for therapeutic use in cancer and other diseases. Named inventors are Yongke Zhang, Guo-Liang Yu, and Weimin Zhu.
What changed
USPTO granted US Patent 12,606,632 B2 to Apexigen, Inc. on April 21, 2026, covering high affinity anti-CD40 monoclonal antibodies and compositions for therapeutic use in cancer and other disease treatment. The patent (12 claims) provides Apexigen enforceable IP rights excluding others from making, using, or selling the claimed invention for the patent term.
Biopharmaceutical and biotechnology companies developing CD40-targeted therapies should review the patent's claims and scope to assess potential freedom-to-operate considerations. Licensing discussions with Apexigen may be warranted for parties working in this immunological pathway space.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Anti-CD40 antibodies and methods of use
Grant US12606632B2 Kind: B2 Apr 21, 2026
Assignee
Apexigen, Inc.
Inventors
Yongke Zhang, Guo-Liang Yu, Weimin Zhu
Abstract
The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
CPC Classifications
C07K 16/2878 C07K 2317/24
Filing Date
2023-03-13
Application No.
18182827
Claims
12
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.